Aurinia Pharmaceuticals INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Tang Capital Management and Kevin Tang have increased their beneficial ownership in Aurinia Pharmaceuticals to 10.0%.
NASDAQ
Kevin Tang, a significant beneficial owner, has been appointed Chief Executive Officer of Aurinia Pharmaceuticals Inc.
NASDAQ
Tang Capital Management and affiliates have increased their beneficial ownership in Aurinia Pharmaceuticals Inc. to 9.2% through recent open market purchases totaling $26.3 million.
NASDAQ
ILJIN SNT and Seoung Eun Huh reduce their beneficial ownership in Aurinia Pharmaceuticals, bringing the group's total stake to 5.0%.
NASDAQ
SCHEDULE 13D/A: Tang Capital Increases Stake in Aurinia Pharmaceuticals to 7.3%
Tang Capital Management and its affiliates have significantly increased their beneficial ownership in Aurinia Pharmaceuticals Inc., now holding 7.3% of the common shares after investing an additional $23.5 million.